Related Experiment Video
Updated: May 14, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
[nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation]
1Apotheke des Universitätsklinikums Tübingen, Röntgenweg 9, 72076 Tübingen. Hans-Peter.Lipp@med.uni-tuebingen.de
Abstract:
Nanoparticle-albumin bound paclitaxel (nab-paclitaxel) represents an innovative taxane-containing formulation lacking any critical solvents with minimal risks for any hypersensitivity reactions as well as perspectives for dose escalation as a consequence. Preclinical data indicated an increase of drug accumulation in tumor tissues via nab-paclitaxel administration which appears to be related to direct interaction with albumin-binding proteins including stromal SPARC. Phase III study results revealed clinically relevant advantages regarding efficacy and tolerability associated with nab-paclitaxel compared to conventional docetaxel and paclitaxel in patients with metastatic breast cancer. Further experience may encourage its use in other tumor entities including NSCLC, ovarian and pancreatic carcinoma as well as melanoma. As a consequence, the development of algorithms is ongoing in order to be able to select patients in more detail who will particularly benefit from nab-paclitaxel treatment.
Related Concept Videos
Drugs that Stabilize Microtubules
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Site-Targeted Drug Delivery Systems: Polymeric Carriers

